Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4T5LH)

• Drug Name: Guanosine Drug Info
• Cross-matching ID:
  PubChem CID: 135398635
  ChEBI ID: CHEBI:16750
  CAS Number: CAS 118-00-3
  TTD Drug ID: DM4T5LH

Molecule-Related Drug Atlas

Drug(s) Targeting Herpes simplex virus DNA polymerase UL30 (HSV UL30)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[5]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[6]
Valaciclovir	DMHKS94	Genital herpes	1A94	Approved	[7]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[5]
Valganciclovir	DMS2IUH	Virus infection	1A24-1D9Z	Approved	[8]
Penciclovir	DMOUMDV	Herpes simplex labialis	1F00.01	Approved	[9]
Famciclovir	DMJHLSD	Meniere disease	AB31.0	Approved	[10]
Valacyclovir Hydrochloride	DM5I1CE	Herpes simplex virus infection	1F00	Approved	[5]
Foscavir	DM9KJLZ	Cytomegalovirus retinitis	9B72.00	Approved	[8]

Drug(s) Targeting Purine nucleoside phosphorylase (PNP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BCX-3408	DMRSG31	Autoimmune diabetes	5A10	Phase 2	[11]
2'3'-Dideoxyinosine	DMZWNQF	N. A.	N. A.	Phase 2	[1]
Forodesine	DME2W4T	B-cell acute lymphoblastic leukaemia	2B33.3	Phase 1/2	[12]
Peldesine	DMHV58T	N. A.	N. A.	Phase 1	[1]
CI-972	DM9ZBO0	Rheumatoid arthritis	FA20	Discontinued in Phase 1	[13]
7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)	DMSU06X	Discovery agent	N.A.	Investigative	[14]
Hypoxanthine	DMLSABI	Discovery agent	N.A.	Investigative	[1]
8-Iodo-Guanine	DM3K1EO	Discovery agent	N.A.	Investigative	[1]
8-Azaguanine	DM7VP90	Discovery agent	N.A.	Investigative	[1]
MT-Immucillin-H	DMK2FOX	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting Cytomegalovirus DNA polymerase (CMV UL54)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanosine-5'-Monophosphate	DM3SLZK	Discovery agent	N.A.	Investigative	[1]

Drug(s) Affected By Eukaryotic translation initiation factor 4E (EIF4E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[19]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[23]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]

Drug(s) Affected By Equilibrative nucleoside transporter 3 (SLC29A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[27]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[28]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[29]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[30]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[2]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytomegalovirus DNA polymerase (CMV UL54)	TT1U2YM	DPOL_HCMVA	Inhibitor	[1]
Herpes simplex virus DNA polymerase UL30 (HSV UL30)	TTIU7X1	DPOL_HHV11	Inhibitor	[1]
Purine nucleoside phosphorylase (PNP)	TTMCF1Y	PNPH_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Equilibrative nucleoside transporter 3 (SLC29A3)	OTGLX8XU	S29A3_HUMAN	Regulation of Drug Effects	[2]
Eukaryotic translation initiation factor 4E (EIF4E)	OTDAWNLA	IF4E_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
• [3] Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation. Eur J Med Chem. 2016 Nov 29;124:200-217. doi: 10.1016/j.ejmech.2016.08.047. Epub 2016 Aug 24.
• [4] Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81.
• [7] Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15.
• [8] Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
• [9] Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66.
• [10] Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
• [11] BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent. 50th ASH Annual Meeting and Exposition. 2008.
• [12] Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 an... Blood. 2009 Aug 20;114(8):1563-75.
• [13] Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d] pyrimidin-4-one. J Med Chem. 1992 May 1;35(9):1605-9.
• [14] Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. J Biol Chem. 1986 Sep 5;261(25):11667-73.
• [15] Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function. J Biol Chem. 2004 Apr 30;279(18):18103-6.
• [16] Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2022 Jan 15;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.
• [17] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [18] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [19] Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.
• [20] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [21] The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 2007 Dec 1;67(23):11402-10. doi: 10.1158/0008-5472.CAN-07-1792.
• [22] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [23] The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
• [24] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [25] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [26] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [27] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [28] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [29] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [30] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [31] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.